Burkhard Matthes

Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis

Friedemann Schad, Anja Thronicke, Megan L. Steele et al. · PLoS ONE · 2018 · 61 citations · Full text

KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma

Nikolaj Frost, Jens Kollmeier, Claudia Vollbrecht et al. · Translational Lung Cancer Research · 2021 · 55 citations · Full text

Clinical safety of combined therapy of immune checkpoint inhibitors and Viscum album L. therapy in patients with advanced or metastatic cancer

Anja Thronicke, Megan L. Steele, Christian Grah et al. · BMC Complementary and Alternative Medicine · 2017 · 46 citations · Full text

Network Oncology (NO) - a Clinical Cancer Register for Health Services Research and the Evaluation of Integrative Therapeutic Interventions in Anthroposophic Medicine

Friedemann Schad, Jan Axtner, Antje Happe et al. · Complementary Medicine Research · 2013 · 39 citations

Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids

Nikolaj Frost, Jens Kollmeier, Daniel Misch et al. · Clinical Lung Cancer · 2021 · 28 citations

Medicine, Pd-l1 Overexpressing, Pharmacology +8